Oncad for DynaCAD is an FDA-cleared, fully automated morphological system for the detection and analysis by a radiologist of suspicious breast lesions. It uses a patented mathematical algorithm to analyze the entire breast and draw a physician’s attention to abnormal morphology during a contrast-enhanced breast MRI. This approach also delineates the extent of the disease by measuring margin sharpness to determine the degree of lesion vascularization. The suspicious lesions are marked with a color overlay, light pink for moderate suspicion and dark pink for highly suspicious lesions.

For more information: www.invivocorp.com


Related Content

News | Women's Health

April 16, 2026 – GE HealthCare has expanded its collaboration with DeepHealth, Inc., a wholly-owned subsidiary of RadNet ...

Time April 20, 2026
arrow
News | FDA

April 16, 2026 — Royal Philips has received U.S. Food and Drug Administration 510(k) clearance for the Philips Spectral ...

Time April 20, 2026
arrow
News | Breast Imaging

April 15, 2026 — QT Imaging Holdings, Inc. has launched its QTI Imaging-Olea Viewer, developed in collaboration with ...

Time April 15, 2026
arrow
News | Radiology Imaging

April 7, 2026 — Onvida Health and Siemens Healthineers have entered a 10-year Value Partnership¹ designed to bring the ...

Time April 09, 2026
arrow
News | Radiology Business

March 31, 2026 — Radon Medical Imaging, a medical imaging equipment maintenance and repair services company, has has ...

Time March 31, 2026
arrow
News | Radiology Imaging

March 26, 2026 — GE HealthCare has announced a renewed research collaboration with Stanford Medicine Department of ...

Time March 30, 2026
arrow
News | Radiology Education

March 17, 2026 – The Center for Radiology Education (CRE) has announced a nationwide initiative to provide scholarships* ...

Time March 17, 2026
arrow
News | Radiology Business

March 12, 2026 — DelveInsight's has released its latest Diagnostic Imaging Equipment Market Insights report. The in ...

Time March 13, 2026
arrow
Feature | Artificial Intelligence | Kyle Hardner

Once considered an adjunct brain cancer therapy and a last-resort treatment, noninvasive radiosurgery has evolved ...

Time March 09, 2026
arrow
News | Women's Health

March 4, 2026 — QT Imaging Holdings recently announced that Mary W. Yamashita, MD will serve as medical advisor to the ...

Time March 06, 2026
arrow
Subscribe Now